SRTA — Strata Critical Medical, Inc.

SRTA Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 2025 Revenue: $66.8 million, a 35.3% increase from the prior year, driven primarily by logistics growth.
• Full-Year 2025 Revenue: $197.1 million, exceeding guidance.
• Adjusted EBITDA for Q4 2025: $7.0 million, up from $1.1 million year-over-year.
• Gross Profit: Increased 90% to $14.4 million in Q4, with a gross margin of 21.6%.
• Operating Cash Flow: Negative $8.3 million, impacted by nonrecurring items and working capital delays.
• Cash Position: Ended the quarter with approximately $61.0 million in cash and short-term investments, with no debt.

2. Strategic Updates and Business Highlights:

• Organic Growth: Achieved 35% organic growth in Q4, leading to an increase in full-year guidance for 2026.
• Acquisition Strategy: Continued focus on acquiring smaller businesses to enhance growth and geographical reach. A $30 million asset-based credit facility was secured to support this strategy.
• Regulatory Alignment: Positive regulatory developments are expected to benefit the company, particularly regarding DCD organ recovery.
• Operational Changes: Expanded leadership with Dr. Scott Silvestri appointed as Chief Medical Officer, enhancing clinical capabilities.
• Aircraft Fleet: Ended the year with approximately 30 aircraft; one aircraft was parted out due to corrosion, resulting in a book loss of $1.7 million.

3. Forward Guidance and Outlook:

• 2026 Revenue Guidance: Raised to $260–$275 million from $255–$270 million.
• Adjusted EBITDA Guidance: Increased to $29–$33 million from $28–$32 million.
• Free Cash Flow Guidance: Reiterated at $15–$22 million.
• Q1 2026 Expectations: Anticipate a modest sequential revenue decline due to seasonal factors and weather impacts, but expect improvement in Q2 and the second half of the year.

4. Bad News, Challenges, or Points of Concern:

• Operating Cash Flow: Negative cash flow in Q4 due to nonrecurring items and working capital issues.
• Weather Impact: Severe weather in the Northeast affected operations and may lead to a temporary decline in Q1 revenues.
• Regulatory Scrutiny: While regulatory changes could benefit the company, they also present challenges as the industry adapts to new standards.
• Rising Costs: Increased fuel prices could impact customer costs, though these are typically passed through to customers.

5. Notable Q&A Insights:

• Regulatory Policy Updates: Continuous distribution policy for organ allocation is progressing, with lungs already transitioned. Hearts and livers are deprioritized currently.
• Acquisition Pipeline: The company is actively pursuing acquisitions in its core competency areas, with plans to announce new deals as they close.
• Radiopharmaceuticals: Currently piloting services in this area but not planning immediate acquisitions; focus remains on core business lines.
• Customer Acquisition: New customer wins are encouraging, with a focus on integrating logistics and clinical services to enhance value.
• Weather and Trip Mix: Recent shorter trips are attributed to customer dynamics rather than a shift in strategy, with overall trip volumes remaining strong.

Overall, Strata Critical Medical, Inc. reported a strong quarter with significant growth, strategic acquisitions, and positive regulatory developments, while also facing challenges related to cash flow and external factors like weather and rising costs.